| Study Method |
Study Method |
| Jin et al. [64] |
Systemic delivery of rhOPG-Fc |
| Teng et al. [55] |
Intraperitoneal injection of srOPG-Fc |
| Valverde et al. [76] |
Subcutaneous kaliotoxin, K+-channel blocker T cells. |
| Kawai et al. [77] |
Intraperitoneal injection of OPG-Fc |
| Mahamed et al. [78] |
Intraperitoneal injection of hu-OPG-Fc |
| Rogers et al. [79] |
Oral gavage of SD282, a p38 MAPK inhibitor |
| Assuma et al. [14] |
Intrapapillary injection of TNF-alpha and IL-1 antagonists. |
rhOPG-Fc: Human recombinant osteoprotegerin fusion protein; MAPK: Mitogen-
Activated Protein Kinase; SFRP1: Secreted Frizzled-related Protein 1; hOPGFc:
Human Osteoprotegerin fusion protein; srOPG-Fc: soluble recombinant
Osteoprotegerin fusion protein; huOPG-Fc: human osteoprotegerin fusion protein;
SD282: an indole 5-carboxamide selective p38* MAPK inhibitor (Scois, Fremont,
CA). (David L Cochran)